This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

deferasirox (Exjade®)

Reference No. 1621

Publication date:

Appraisal information

deferasirox (Exjade®) 125 mg dispersible tablet
deferasirox (Exjade®) 250 mg dispersible tablet
deferasirox (Exjade®) 500 mg dispersible tablet

Company: Novartis Pharmaceuticals UK Ltd
BNF category: Nutrition and blood
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 29/07/2013

Current Progress

Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, deferasirox (Exjade®) cannot be endorsed for use within NHS Wales for the treatment of chronic iron overload requiring chelation therapy, when deferoxamine therapy is contraindicated or inadequate in patients with non-transfusion-dependent thalassaemia syndromes aged 10 years and older.
Statement of Advice (SOA)